La chaîne d'options affiche les données clés des options sur actions de BiomX à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour BiomX..

BiomX (AMEX:PHGE) Stock, Chaîne d'Options

BIOMX INC

BiomX

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

BiomX Inc

BiomX Inc Warrants (13/12/2023)

Earnings

Press Releases

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

News

General

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

BiomX Stock Could Soar 3000% As This $10M Biotech Cracks The 'Superbug' Code, Wall Street Says

This $13M Biotech Has $40M in Pentagon Funding – Here's Why BiomX Could Be Biotech's Best-Kept Secret

Health Care

Markets

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

Market Alert: BiomX Trading Surges Following Phase 2b Trial Initiation in Cystic Fibrosis Program

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

Next-Gen Leaders: SIGL, PHGE, OTRK, SGBX – Across Critical Sectors

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

ARMP

NVDA

OTRK

PHGE

SGBX

Abpro Hldgs

Ainos

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Edesa Biotech

Ernexa Therapeutics

Evogene

iBio

IN8bio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Longeveron

Marker Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

NextCure

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Pelthos Therapeutics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

BiomX

BiomX (PHGE) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL